Walleye Capital’s Revelation Biosciences REVB Stock Holding History

Walleye Capital’s Portfolio REVB Stock Details REVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-72	Closed	-$207K	–	5820
2023 Q4	$207K	Buy	72 +4	+6%	+$14.3K	﹤0.01%	3654
2023 Q3	$266K	Buy	68 +14	+26%	+$61.8K	﹤0.01%	3333
2023 Q2	$293K	Buy	54 +24	+80%	+$150K	﹤0.01%	2827
2023 Q1	$227K	Buy	+30	New	+$810K	﹤0.01%	2367
2021 Q4	–	Hold	0	–	-$256K	–	2273
2021 Q3	–	Hold	0	–	–	–	1098
2021 Q2	–	Hold	0	–	–	–	586
2021 Q1	–	Hold	0	–	–	–	428

Other funds holding REVB

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

PIS

POM Investment Strategies Raleigh, North Carolina $88.3M AUM 15.23% 1-Year Est. Return

Walleye Capital's REVB Position: Q1 2024 in Review

Walleye Capital sold out of Revelation Biosciences (REVB) in Q1 2024, closing a stake of 72 shares — an estimated $207K sold.

Walleye Capital first reported a position in REVB in Q1 2023 and held it in 4 quarters. The position peaked at $293K in Q2 2023. 3 funds tracked by Wall St. Rank hold REVB as of Q1 2024.

Walleye Capital reported no remaining Revelation Biosciences position as of Q1 2024 after selling out during the quarter.
Walleye Capital sold 72 Revelation Biosciences shares in Q1 2024, an estimated $207K.
Walleye Capital first reported a position in Revelation Biosciences in Q1 2023 and held it in 4 quarters.
Walleye Capital's Revelation Biosciences position peaked at $293K in Q2 2023.
3 funds tracked by Wall St. Rank held Revelation Biosciences as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.